Abstract
While work to combat immune rejection of animal organs is progressing, concerns remain as to the risks of disease transmission.
This is a preview of subscription content, log in via an institution to check access.
References
Reemtsma, K. et al. Science 143, 700–702 (1964).
Reemtsma, K. et al. JAMA 187, 691–696 (1964).
Hitchcock, C.R. et al. JAMA 198, 934–937 (1964).
Starzl, T.E. et al. Transplantation 2, 752–776 (1964).
Persidis, A. Nat. Biotechnol. 16, 882–883(1998).
Auchincloss, H. Jr, and Sachs, D.H. Ann. Rev. Immunol. 16, 433–470 (1998).
Xiao, F. et al. Transplantation 58, 828–834 (1994).
Fishman, J.A. Xenotransplantation 1, 47–57 (1994).
Murphy, F.A. Science 273, 746–747 ( 1998).
Starzl, T.E. et al. Lancet 341, 65–71 (1993).
Groth, C.G. et al. Tranplant. Proc. 28, 538– 539 (1996).
Deacon, T. et al. Nat. Med. 3, 350–353 ( 1997).
Xue, Y.L. et al. Artif. Cells. Blood Substit. Immobil. Biotechnol. 28, 337–345 (2000).
Ildstad, S.T. Lancet 347, 761 (1996).
Cozzi, E. et al. Transplantation 70, 15–21 (2000).
Bracy, J.L. et al. Science 281, 1845–1847 (1998).
Kobayashi, N. et al. Transplant Proc. 32, 1123– 1124 (2000).
Aomatsu, Y. et al, Transplant Proc. 32, 1071– 1072 (2000).
Cooper, D.K. Xenotransplantation 5, 6–17(1998).
Dyer, M.R. & Herrling, P.L. Mol. Ther. 1, 213–224 (2000).
Rights and permissions
About this article
Cite this article
Xenotransplantation. Nat Biotechnol 18 (Suppl 10), IT53–IT55 (2000). https://doi.org/10.1038/80100
Issue Date:
DOI: https://doi.org/10.1038/80100
- Springer Nature America, Inc.
This article is cited by
-
Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses
Cancer Cell International (2018)
-
Silencing porcine genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation
Transgenic Research (2016)